Pharma Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the company and the growth ambitions for the affiliate over the next few years. You have extensive experience in the generics…
Pharma Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014: improving competitiveness, renewing innovative capabilities, increasing operational excellence, and lastly, furthering international development. Mr Duchesne also reveals how in 2015…
infrastructure Dogan Taşkent, president of the Swiss Chamber of Commerce in Turkey discusses the most successful models for innovation in Turkey, the current status of start-up incubators in the country, and how Turkey can learn from the Swiss model for innovation. What are the main economic challenges that Turkey is facing…
scienfitic output João Lobo Antunes, Founder of Institute of Molecular Medicine (IMM), Portugal gives his insights into Portugal’s strengths in science and technology, as well as his ambitions to grow IMM into one of the world’s leading institutes for genomics. How would you rate Portugal’s scientific output nationwide? The scientific development…
Pharmaceutical Benefits Advisory Committee To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the Ministry of Health and Ageing as to what drugs will be listed on the Pharmaceutical Benefits Scheme (PBS). The Minister…
See our Cookie Privacy Policy Here
